Piper Sandler upgrades Alpha Tau Medical to Overweight and lifts target to $22
Piper Sandler upgraded Alpha Tau Medical to Overweight and raised its price target to $22 a share, pointing to upcoming REGAIN and ReSTART U.S. data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Alpha Tau Medical shares rose on Wednesday after Piper Sandler upgraded the oncology company to Overweight from Neutral, according to Seeking Alpha. Analyst Allison Bratzel pointed to a busy run of catalysts over the next 12 months and sees Alpha DaRT, the company's alpha-radiation cancer therapy, as a differentiated technology that could address several solid tumors.
The nearest event is an update on the REGAIN study in recurrent glioblastoma, due at the Society for Neuro-Oncology annual meeting on November 13. Bratzel also expects topline data from the ReSTART U.S. trial in recurrent cutaneous squamous cell carcinoma in late 2026 or early 2027. She raised her price target to $22 from $8 a share.
why it matters
A rating change from a single brokerage typically moves one smaller stock rather than the broader market. For Alpha Tau, attention now shifts to the SNO data and the ReSTART readout, which the analyst described as the company's first registrational-stage result.
market impact
Alpha Tau Medical: the upgrade supports interest in the stock ahead of upcoming trial data
tags
instruments
sources
- Alpha Tau upgraded at Piper Sandler on catalyst path — Seeking Alpha, 11 November 2026 at 16:32 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗